JAK Inhibition Impairs NK Cell Function in Myeloproliferative Neoplasms

Cancer Research - Tập 75 Số 11 - Trang 2187-2199 - 2015
Kathrin Schönberg1, Janna Rudolph1, Maria Vonnahme1, Sowmya Parampalli Yajnanarayana1, Isabelle Cornez1, Maryam Hejazi2, Angela R. Manser2, Markus Uhrberg2, Walter Verbeek3, Steffen Koschmieder4, Tim H. Brümmendorf4, Peter Brossart1, Annkristin Heine1, Dominik Wolf‎1
11Medical Clinic, Oncology, Hematology and Rheumatology, University Clinic Bonn (UKB), Bonn, Germany.
22Institute for Transplantation Diagnostics and Cell Therapeutics, University Clinic Düsseldorf, Düsseldorf, Germany.
33ZAHO, Bonn, Germany.
44Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, Aachen, Germany.

Tóm tắt

Abstract Ruxolitinib is a small-molecule inhibitor of the JAK kinases, which has been approved for the treatment of myelofibrosis, a rare myeloproliferative neoplasm (MPN), but clinical trials are also being conducted in inflammatory-driven solid tumors. Increased infection rates have been reported in ruxolitinib-treated patients, and natural killer (NK) cells are immune effector cells known to eliminate both virus-infected and malignant cells. On this basis, we sought to compare the effects of JAK inhibition on human NK cells in a cohort of 28 MPN patients with or without ruxolitinib treatment and 24 healthy individuals. NK cell analyses included cell frequency, receptor expression, proliferation, immune synapse formation, and cytokine signaling. We found a reduction in NK cell numbers in ruxolitinib-treated patients that was linked to the appearance of clinically relevant infections. This reduction was likely due to impaired maturation of NK cells, as reflected by an increased ratio in immature to mature NK cells. Notably, the endogenous functional defect of NK cells in MPN was further aggravated by ruxolitinib treatment. In vitro data paralleled these in vivo results, showing a reduction in cytokine-induced NK cell activation. Further, reduced killing activity was associated with an impaired capacity to form lytic synapses with NK target cells. Taken together, our findings offer compelling evidence that ruxolitinib impairs NK cell function in MPN patients, offering an explanation for increased infection rates and possible long-term side effects associated with ruxolitinib treatment. Cancer Res; 75(11); 2187–99. ©2015 AACR.

Từ khóa


Tài liệu tham khảo

Tefferi, 2000, Myelofibrosis with myeloid metaplasia, N Engl J Med, 342, 1255, 10.1056/NEJM200004273421706

Schindler, 2007, JAK-STAT signaling: from interferons to cytokines, J Biol Chem, 282, 20059, 10.1074/jbc.R700016200

Percy, 2005, The V617F JAK2 mutation and the myeloproliferative disorders, Hematol Oncol, 23, 91, 10.1002/hon.761

Harrison, 2012, JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis, N Engl J Med, 366, 787, 10.1056/NEJMoa1110556

Verstovsek, 2012, A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis, N Engl J Med, 366, 799, 10.1056/NEJMoa1110557

Santos, 2012, JAK2 inhibitors for myelofibrosis: why are they effective in patients with and without JAK2V617F mutation?, Anti-cancer Agents Med Chem, 12, 1098, 10.2174/187152012803529727

Colomba, 2012, Disseminated tuberculosis in a patient treated with a JAK2 selective inhibitor: a case report, BMC Res Notes, 5, 552, 10.1186/1756-0500-5-552

Hopman, 2014, Disseminated tuberculosis associated with ruxolitinib, Leukemia, 28, 1750, 10.1038/leu.2014.104

Caocci, 2014, Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis, Leukemia, 28, 225, 10.1038/leu.2013.235

Wathes, 2013, Progressive multifocal leukoencephalopathy associated with ruxolitinib, N Engl J Med, 369, 197, 10.1056/NEJMc1302135

Goldberg, 2013, Bilateral toxoplasmosis retinitis associated with ruxolitinib, N Engl J Med, 369, 681, 10.1056/NEJMc1302895

Hurwitz, 2014, A randomized double-blind phase 2 study of ruxolitinib (RUX) or placebo (PBO) with capecitabine (CAPE) as second-line therapy in patients (pts) with metastatic pancreatic cancer (mPC), J Clin Oncol, 32, 5s, 10.1200/jco.2014.32.15_suppl.4000

Heine, 2013, The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo, Blood, 122, 1192, 10.1182/blood-2013-03-484642

Vivier, 2008, Functions of natural killer cells, Nat Immunol, 9, 503, 10.1038/ni1582

Lanier, 2008, Up on the tightrope: natural killer cell activation and inhibition, Nat Immunol, 9, 495, 10.1038/ni1581

Ortmann, 2000, Janus kinases and signal transducers and activators of transcription: their roles in cytokine signaling, development and immunoregulation, Arthritis Res, 2, 16, 10.1186/ar66

Schonberg, 2012, Protocol for the clonal analysis of NK cell effector functions by multi-parameter flow cytometry, Methods Mol Biol, 903, 381, 10.1007/978-1-61779-937-2_26

Schonberg, 2011, Analyses of HLA-C-specific KIR repertoires in donors with group A and B haplotypes suggest a ligand-instructed model of NK cell receptor acquisition, Blood, 117, 98, 10.1182/blood-2010-03-273656

Cornez, 2013, EGF signalling and rapamycin-mediated mTOR inhibition in glioblastoma multiforme evaluated by phospho-specific flow cytometry, J Neurooncol, 112, 49, 10.1007/s11060-012-1035-9

Hazeldine, 2013, The impact of ageing on natural killer cell function and potential consequences for health in older adults, Ageing Res Rev, 12, 1069, 10.1016/j.arr.2013.04.003

Fu, 2011, CD11b and CD27 reflect distinct population and functional specialization in human natural killer cells, Immunology, 133, 350, 10.1111/j.1365-2567.2011.03446.x

Chiossone, 2009, Maturation of mouse NK cells is a 4-stage developmental program, Blood, 113, 5488, 10.1182/blood-2008-10-187179

Juelke, 2009, Education of hyporesponsive NK cells by cytokines, Eur J Immunol, 39, 2548, 10.1002/eji.200939307

Anfossi, 2006, Human NK cell education by inhibitory receptors for MHC class I, Immunity, 25, 331, 10.1016/j.immuni.2006.06.013

Shilling, 2010, Metabolism, excretion, and pharmacokinetics of [14C]INCB018424, a selective Janus tyrosine kinase 1/2 inhibitor, in humans, Drug Metab Dispos, 38, 2023, 10.1124/dmd.110.033787

Tefferi, 2011, Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis, Mayo Clin Proc, 86, 1188, 10.4065/mcp.2011.0518

Colucci, 2003, What does it take to make a natural killer?, Nat Rev Immunol, 3, 413, 10.1038/nri1088

Miller, 2001, Human natural killer cells with polyclonal lectin and immunoglobulinlike receptors develop from single hematopoietic stem cells with preferential expression of NKG2A and KIR2DL2/L3/S2, Blood, 98, 705, 10.1182/blood.V98.3.705

Gilmour, 2001, Defective expression of the interleukin-2/interleukin-15 receptor beta subunit leads to a natural killer cell-deficient form of severe combined immunodeficiency, Blood, 98, 877, 10.1182/blood.V98.3.877

Cooper, 2002, In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells, Blood, 100, 3633, 10.1182/blood-2001-12-0293

Vosshenrich, 2005, Roles for common cytokine receptor gamma-chain-dependent cytokines in the generation, differentiation, and maturation of NK cell precursors and peripheral NK cells in vivo, J Immunol, 174, 1213, 10.4049/jimmunol.174.3.1213

Ranson, 2003, IL-15 is an essential mediator of peripheral NK-cell homeostasis, Blood, 101, 4887, 10.1182/blood-2002-11-3392

Roberts, 2004, Janus kinase 3 (JAK3) deficiency: clinical, immunologic, and molecular analyses of 10 patients and outcomes of stem cell transplantation, Blood, 103, 2009, 10.1182/blood-2003-06-2104

Bernasconi, 2006, Characterization of immunodeficiency in a patient with growth hormone insensitivity secondary to a novel STAT5b gene mutation, Pediatrics, 118, e1584, 10.1542/peds.2005-2882

Lin, 2000, The role of Stat5a and Stat5b in signaling by IL-2 family cytokines, Oncogene, 19, 2566, 10.1038/sj.onc.1203523

Quintas-Cardama, 2010, Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms, Blood, 115, 3109, 10.1182/blood-2009-04-214957

Zhou, 2014, Specificity and mechanism-of-action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348), Leukemia, 28, 471, 10.1038/leu.2013.299

Gorantla, 2013, Ruxolitinib mediated paradox JAK2 hyperphosphorylation is due to the protection of activation loop phosphotyrosines from phosphatases, ASH

Bogani, 2007, B-, T-, and NK-cell lineage involvement in JAK2V617F-positive patients with idiopathic myelofibrosis, Haematologica, 92, 258, 10.3324/haematol.10527

Froom, 1989, Decreased natural killer (NK) activity in patients with myeloproliferative disorders, Cancer, 64, 1038, 10.1002/1097-0142(19890901)64:5<1038::AID-CNCR2820640513>3.0.CO;2-W

Gersuk, 1993, Quantitative and functional studies of impaired natural killer (NK) cells in patients with myelofibrosis, essential thrombocythemia, and polycythemia vera. I. A potential role for platelet-derived growth factor in defective NK cytotoxicity, Nat Immun, 12, 136

Almeida-Oliveira, 2011, Age-related changes in natural killer cell receptors from childhood through old age, Hum Immunol, 72, 319, 10.1016/j.humimm.2011.01.009

Orange, 2008, Formation and function of the lytic NK-cell immunological synapse, Nat Rev Immunol, 8, 713, 10.1038/nri2381

Bellucci, 2012, Tyrosine kinase pathways modulate tumor susceptibility to natural killer cells, J Clin Invest, 122, 2369, 10.1172/JCI58457

Spoerl, 2014, Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease, Blood, 123, 3832, 10.1182/blood-2013-12-543736

Ruggeri, 2002, Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants, Science, 295, 2097, 10.1126/science.1068440

Jost, 2013, Control of human viral infections by natural killer cells, Annu Rev Immunol, 31, 163, 10.1146/annurev-immunol-032712-100001

Orange, 2013, Natural killer cell deficiency, J Allergy Clin Immunol, 132, 515, 10.1016/j.jaci.2013.07.020

Tong, 2014, Reactivation of herpes simplex virus infection in a patient undergoing ruxolitinib treatment, J Am Acad Dermatol, 70, e59, 10.1016/j.jaad.2013.09.035

Parampalli Yajnanarayana, 2015 30, JAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms, Br J Haematol, 10.1111/bjh.13373

Thông tin
Thông tin xuất bản

Cancer Research

Tập 75 Số 11

2187-2199

Thông tin tác giả